AbbVie Inc (ABBV)vsTriSalus Life Sciences Inc. (TLSI)
ABBV
AbbVie Inc
$206.60
-2.23%
HEALTHCARE · Cap: $360.63B
TLSI
TriSalus Life Sciences Inc.
$4.39
+1.62%
HEALTHCARE · Cap: $275.75M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 135357% more annual revenue ($61.16B vs $45.15M). ABBV leads profitability with a 6.9% profit margin vs -86.9%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
TLSI
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.3%
Fair Value
$163.59
Current Price
$206.60
$43.01 premium
Margin of Safety
-51.4%
Fair Value
$3.15
Current Price
$4.39
$1.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 59.8% year-over-year
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -496.2% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : TLSI
The strongest argument for TLSI centers on Revenue Growth. Revenue growth of 59.8% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : TLSI
The primary concerns for TLSI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while TLSI is a hypergrowth play — different risk/reward profiles.
TLSI carries more volatility with a beta of 0.54 — expect wider price swings.
TLSI is growing revenue faster at 59.8% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 25/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
TriSalus Life Sciences Inc.
HEALTHCARE · MEDICAL DEVICES · USA
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical company at the forefront of transforming cancer therapy through its proprietary localized drug delivery systems. By optimizing the efficacy of immuno-oncology agents and tackling significant distribution hurdles within the tumor microenvironment, TriSalus aims to enhance therapeutic outcomes for cancer patients. The company boasts a compelling pipeline of clinical programs that underscore its dedication to addressing the pressing need for advanced cancer treatments. With a strategic vision centered on expanding access to these critical therapies, TriSalus is positioned to be a significant player in the evolving oncology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?